Exchange: NASDAQ·Updated 07:30 AM EDT
CALC logo

CALCCalciMedica Inc

$1.01
$0.03
(2.88%)
Pre-Market
Prev Close $1.04
Mkt Cap$16.27M
Vol13,403.00
News
all
press releases
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program PR Newswire LA JOLLA, Calif., June 24, 2026...
PR Newswire
News Placeholder
More News
News Placeholder
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data PR Newswire LA JOLLA, Calif., June 24, 2026 FDA...
PR Newswire
News Placeholder
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates...
PR Newswire
News Placeholder
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates CalciMedica Reports 2025 Financial Results and Provides Clinical Updates PR Newswire LA JOLLA, Calif., March 3, 2026 Internal...
PR Newswire
News Placeholder
How Is The Market Feeling About CalciMedica Inc?
read more...
Benzinga
News Placeholder
CALC Stock Slumped 76% On Wednesday — Here’s Why
CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation.
Stocktwits
News Placeholder
CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen
Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...
MarketBeat
News Placeholder
CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?
CalciMedica (NASDAQ:CALC) Stock Price Down 2.1% - Time to Sell...
MarketBeat
News Placeholder
Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC
Stonepine Capital Management LLC lowered its stake in shares of CalciMedica Inc. (NASDAQ:CALC - Free Report) by 76.9% during the second quarter, according to the company in its most recent filing...
MarketBeat
News Placeholder
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.